论文部分内容阅读
目的 :探讨乳房恶性肿瘤组织中端粒酶活性的表达情况及p16抑癌基因的影响。方法 :应用端粒重复放大程序 酶标法 (TRAP ELISA)及TRAP 银染法检测 35例乳癌组织及 2 4例良性肿瘤组织中的端粒酶活性 ,并采用多重PCR技术对乳癌组织的p16基因的缺失突变进行了分析。结果 :35例乳癌标本中有 2 8例端粒酶活性表达为阳性 (80 % ) ,而 2 4例乳房良性肿瘤标本中仅 1例端粒酶活性表达阳性 (4 1% )。此外 35例乳癌标本中的 15例存在有 p16基因的外显子 2及外显子 1的缺失 (4 2 8% ) ,而该 15例中有 14例被检测为端粒酶活性阳性 (93.3% ) ,但 2 0例未缺失标本的端粒酶阳性率仅为 70 % (14/2 0 )。结论 :端粒酶活性与乳房肿瘤组织的恶性程度密切相关 ,提示端粒酶参与了肿瘤的形成过程 ,而端粒酶活性的增高与p16抑癌基因的缺失突变之间可能存在有一定的关系。
Objective: To investigate the expression of telomerase activity and the effect of p16 oncogene in breast malignant tumors. Methods: Telomerase activity in 35 breast cancer tissues and 24 benign tumor tissues was detected by TRAP ELISA and TRAP silver staining. The p16 gene in breast cancer tissues The deletion mutation was analyzed. RESULTS: Twenty-eight of 35 breast cancer samples were positive for telomerase activity (80%), while only 1 of 24 breast benign tumor samples showed positive telomerase activity (41%). In addition, 15 out of 35 breast cancers had exon 2 and exon 1 deletions (42.8%) of the p16 gene, while 14 of these 15 cases were detected as telomerase positive (93.3 %). However, the positive rate of telomerase in 20 non-deleted samples was only 70% (14/2). CONCLUSION: Telomerase activity is closely related to the malignancy of breast tumor tissue, suggesting that telomerase is involved in tumor formation. However, there may be a relationship between the increase of telomerase activity and deletion mutation of p16 tumor suppressor gene .